

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10531560	
	Filing Date		2006-01-27	
	First Named Inventor	Ian A. SHIELDS et al.		
	Art Unit	1654		
	Examiner Name	BRADLEY, Christina		
Attorney Docket Number		36672.6		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10531560
Filing Date	2006-01-27
First Named Inventor	Ian A. SHIELDS et al.
Art Unit	1654
Examiner Name	BRADLEY, Christina
Attorney Docket Number	36672.6

1	ANAYA et al., "Pulmonary Involvement in Rheumatoid Arthritis," Semin. Arthritis Rheum., 24(4): 242-254, February 1995.	<input type="checkbox"/>
2	ARUMUGAM et al., "A Small Molecule C5a Receptor Antagonist Protects Kidneys from Ischemia/Reperfusion Injury in Rats," Kidney International, 63:134-42, January 2003.	<input type="checkbox"/>
3	ARUMUGAM et al., "Protective Effect of a New C5a Receptor Antagonist against Ischemia-Reperfusion Injury in the Rat Small Intestine," J. Surg. Res., 103:260-7, April 2002.	<input type="checkbox"/>
4	BASKARAN et al., "Dynamics of Tissue Neutrophil Sequestration After Cutaneous Burns in Rats," J. Surg. Res., 93 (1):88-96, September 2000.	<input type="checkbox"/>
5	BEAMES et al., "Studies on Intramolecular Alkylation. IV" The Preparation of Spirodienones from Phenolic Diazoketones" Aus. J. Chem., 27(6):1257-68, June 1974.	<input type="checkbox"/>
6	BENOITION et al., "Studies on Sensitivity to Racemization of Activated Residues in Couplings of N-benzoyloxycarbonyl dipeptides," Int. J. Pep. Prot. Res., 40(6):559-66, December 1992.	<input type="checkbox"/>
7	BERNADELLI et al., "Section VII. Trends and Perspectives," Ann. Rep. Med. Chem., 37:257-277, October 2002.	<input type="checkbox"/>
8	BERTRAND et al., "CCR3 Blockade as a New Therapy for Asthma," Exp. Opin. Invents. Drugs 9(1):43-52, January 2000.	<input type="checkbox"/>
9	BODANSKY et al., "Introductions of Amine Protecting Groups," The Practice of Peptide Synthesis, 2nd, rev. ed., Springer-Verlag: Berlin, New York, June 1994.	<input type="checkbox"/>
10	BRADY et al., "Large-Scale Synthesis of a Cyclic Hexapeptide Analogue of Somatostatin," J. Org. Chem., 52(5):764-769, March 1987.	<input type="checkbox"/>
11	CAIN et al., "Modulation of Ligand Selectivity by Mutation of the First Extracellular Loop of the Human C5a Receptor," Biochem. Pharmacol., 61(12):1571-9, June 15, 2001.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10531560
Filing Date	2006-01-27
First Named Inventor	Ian A. SHIELDS et al.
Art Unit	1654
Examiner Name	BRADLEY, Christina
Attorney Docket Number	36672.6

12	CHAN et al., "Basic Procedures" in Fmoc Solid Phase Peptide Synthesis: A Practical Approach; Oxford University Press, 2000.	<input type="checkbox"/>
13	CHENG, "Section VII. Trends and Perspectives," Annual Reports in Medicinal Chemistry, 31:337-355, February 1995.	<input type="checkbox"/>
14	DINARELLO, "Dissociation of Transcription from Translation of Human IL-1B: Induction of Steady State mRNA by Adherence or Recombinant C5a in the Absence of Translation," Soc. Exp. Biol. Med., 200:228-232, June 1992.	<input type="checkbox"/>
15	DIOP et al. "Pregabalin (CI-1008) Inhibits the Trinitrobenzene Sulfonic Acid-Induced Chronic Colonic Allodynia in the Rat," J. Pharmacol. Exp. Ther., http://jpet.aspetjournals.org , 302(3):1013-1022, September 2002.	<input type="checkbox"/>
16	FIELDS et al., "Solid Phase Peptide Synthesis Utilizing 9-fluorenylmethoxycarbonyl Amino Acids," Int. J. Pept. Prot. Res., 35(3):161-214, March 1990.	<input type="checkbox"/>
17	FUKUNAGA et al., "A Novel Diamino-Pyridine Derivative (IS-741) Attenuates Rat Ileitis Induced by Trinitrobenzene Sulfonic Acid," J. Gastroenterology, Springer-Verlag, 38(5):451-9, May 2003.	<input type="checkbox"/>
18	GALATIS, P., "Section VII. Trends and Perspectives," Annu. Rep. Med. Chem., " 32:305-326, 1997.	<input type="checkbox"/>
19	GAO et al., "Recent Advances in Neurokinin Receptor Antagonists," Curr. Med. Chem., 6(5):375-388, May 1999.	<input type="checkbox"/>
20	GAUDILLIERE et al. "Section VII. Trends and Perspectives," Annu. Rep. Med. Chem., " 36:293-318, 2001.	<input type="checkbox"/>
21	GAUDILLIERE et al., "Section VII. Trends and Perspectives," Annu. Rep. Med. Chem., 35:331-356, 2000.	<input type="checkbox"/>
22	HARKIN et al., "Complement C5a Receptor Antagonist Attenuates Multiple Organ Injury in a Model of Ruptured Abdominal Aortic Aneurysm," J. Vasc. Surg., 39(1):196-206, January 2004.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10531560
Filing Date	2006-01-27
First Named Inventor	Ian A. SHIELDS et al.
Art Unit	1654
Examiner Name	BRADLEY, Christina
Attorney Docket Number	36672.6

23	HAYNES et al., "Inhibition of C5a-Induced Neutrophil Chemotaxis and Macrophage Cytokine Production In Vitro by a New C5a Receptor Antagonist," Biochem. Pharmacol., Australia, 60(5):729-33, September 1, 2000.	<input type="checkbox"/>
24	HELLER et al., "Selection of a C5a Receptor Antagonist from Phage Libraries Attenuating the Inflammatory Response in Immune Complex Disease and Ischemia-Reperfusion Injury," J. Immunol. 163(2):965-94, July 15, 1999.	<input type="checkbox"/>
25	IKEDA et al., "Simvastatin Attenuates Trinitrobenzene Sulfonic Acid-Induced Colitis, But Not Oxazolone-Induced Colitis, Dig. Dis. Sci., 53(7):1869-75, January 2008.	<input type="checkbox"/>
26	JOHNSON et al., "Heterotrimeric G Protein Signalling: Role in Asthma and Allergic Inflammation" J. Allergy Clin. Immunol., 109(4):592-602, April 2002.	<input type="checkbox"/>
27	MAKRIDES, "Therapeutic Inhibition of the Complement System," Pharmacol. Rev., 50(1):59-87, March 1998.	<input type="checkbox"/>
28	MORIKIS et al., "Structural Aspects and Design of Low-Molecular-Mass Complement Inhibitors," Biochem. Soc. Trans., 30(Pt. 6):1026-36, November 2002.	<input type="checkbox"/>
29	MORRIS et al., "Hapten-Induced Model of Chronic Inflammation and Ulceration in the Rat Colon," Gastroenterology, 96(3):795-803, March 1989.	<input type="checkbox"/>
30	OWEN et al., "Chemokine Receptors in Airway Disease: Which Receptor to Target?," Pulmonary Pharmacology and Therapeutics, 14(3):193-202, June 2001.	<input type="checkbox"/>
31	PACKOWSKI et al., "Pharmacological Characterization of Antagonists of the C5a Receptor," Brit. J. Pharmacol., 128(7):1461-66, December 1999.	<input type="checkbox"/>
32	PICCOLO et al., "Chemotactic Mediator Requirements in Lung Injury Following Skin Burns in Rats," Exp. Molec. Pathol., 66(3) 220-226, August 1999.	<input type="checkbox"/>
33	REID et al., "A Convergent Solution-Phase Synthesis of the Macrocyclic Ac-Phe-[Orn-Pro-D-Cha ₂ -Trp-Arg], A Potent New Antiinflammatory Drug," J. Org. Chem., 68(11):4464-4471, May 30, 2003.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10531560
Filing Date	2006-01-27
First Named Inventor	Ian A. SHIELDS et al.
Art Unit	1654
Examiner Name	BRADLEY, Christina
Attorney Docket Number	36672.6

34	ROSCHMANN et al., "Pulmonary Fibrosis in Rheumatoid Arthritis: A Review of Clinical Features and Therapy," Semin. Arthritis Rheum., 16(3):174-185, February 1987.	<input type="checkbox"/>
35	SCHMID et al., "Requirement for C5a In Lung Vascular Injury Following Thermal Trauma to Rat Skin," Shock, 8(2):119-124, March 31, 1997.	<input type="checkbox"/>
36	SCHUDA et al., "A Short and Efficient Synthesis of (3S, 4S)-4-[(tert-Butyloxycarbonyl)amino]-5-cyclohexyl-3-hydroxypentanoic Acid Ethyl Ester," J. Org. Chem., 53:873-875, February 15, 1988.	<input type="checkbox"/>
37	SHORT et al., "Effects of New C5a Receptor Antagonist on C5a- and Endotoxin-Induced Neutropenia in the Rat," Br. J. Pharmacol, 126(3):551-4, February 1999.	<input type="checkbox"/>
38	SMITH, Organic Synthesis, "Linear vs. Convergent Synthesis," 997-999.	<input type="checkbox"/>
39	STEINAUER et al., "Studies on Racemization Associated with the Use of Benzotriazol-1-yl-tris (dimethylamino) Phosphonium Hexafluorophosphate (BOP)," Int. J. Pept. Protein Res., 34(4):295-8, October 1989.	<input type="checkbox"/>
40	STEWART, "Current Therapy for Acromegaly," Trends Endocrinol. Metab., 11(4):128-132, May-June 2000.	<input type="checkbox"/>
41	STRACHAN et al., "Inhibition of Immune-Complex Mediated Dermal Inflammation in Rats Following Either Oral or Topical Administration of a Small Molecule C5a Receptor Antagonist," British J. Pharmacol., 134(8):1778-86, December 2001.	<input type="checkbox"/>
42	STRIETER et al., "Effects of Interferon-1b on Biomarker Expression in Patients with Idiopathic Pulmonary Fibrosis," Am J Resp. Crit. Care, 170(2): 133-140, March 24, 2004.	<input type="checkbox"/>
43	SZEBENI et al., "Complement Activation During Hemorrhagic Shock and Resuscitation in Swine," Shock, 20(4):347-355, October 20, 2003.	<input type="checkbox"/>
44	TAYLOR et al., "Regulators of the Anaphylatoxin C5a", Exp. Opin. Ther. Patents, 10(4):449-458, April 2000.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10531560
Filing Date	2006-01-27
First Named Inventor	Ian A. SHIELDS et al.
Art Unit	1654
Examiner Name	BRADLEY, Christina
Attorney Docket Number	36672.6

45	TOULOUSE et al., "Role of Tachykinin NK2 receptors in Normal and Altered Rectal Sensitivity in Rats," Brit. J. Pharmacol., 129(1):193-199, January 2000.	<input type="checkbox"/>
46	VAN ASSCHE, "Emerging Drugs to Treat Crohn's Disease," Exp. Opin. Emerg. Drugs, 12(1):49-59, March 2007.	<input type="checkbox"/>
47	WONG et al., "Small Molecular Probes for G-Protein-Coupled C5a Receptors: Conformationally Constrained Antagonists Derived from the C Terminus of the Human Plasma Protein C5a," J. Med. Chem., Australia, 41(18):3417-25, August 27, 1998.	<input type="checkbox"/>
48	WOODRUFF et al., "Species Dependence for Binding of Small Molecule Agonist and Antagonists to the C5a Receptor on Polymorphonuclear Leukocytes," Inflammation, 25(3):171-7, June 2001.	<input type="checkbox"/>
49	MITA et al., "Levels of Cysteinyl Leukotriene Receptor mRNA in Human Peripheral Leucocytes: Significantly Higher Expression of Cysteinyl Leukotriene Receptor mRNA in Eosinophils," Clin. Exp. Allergy, 31(11):1714-1723, November 2001.	<input type="checkbox"/>
50	PICCOLO et al., "Role of Chemotactic factors in Neutrophil Activation After Thermal Injury in Rats," Inflammation, 23(4):371-385, August 1999.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.